Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- The International Society of Peritoneal Dialysis Celebrates 40 Years Posted 10-15-2024
- Michael Aragon, MD Article in DocWireNews on Switching from PD to Home HD Posted 10-15-2024
- PD Excellence Academy Offers Three New Courses and Up to 11 CE Credits Posted 09-12-2024
- New Fresenius Versi®HD Now has GuideMe Software Posted 09-12-2024